urgency urinary incontinence

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months

In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 months, and 2% at 6 months, with a median catheterization duration of 37 days (range, 2-203).

Effect: adverse; 8% at 1 month, 4% at 3 months, 2% at 6 months